118
Views
0
CrossRef citations to date
0
Altmetric
Perspectives

"Step" versus "phase" in the clinical development of biosimilars: the correct noun holds the key to success

Pages 25-28 | Published online: 22 Jun 2016

References

  • U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Rockville, MD: FDA; 2012.
  • European Medicines Agency. Guideline on Similar Biological Medicinal Products (Revision). CHMP/437/04 Rev 1. London: European Medicines Agency; 2014.
  • World Health Organization Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBP). Geneva, Switzerland: WHO; 2009.